Author

Zheng Yao

Institutions: China Pharmaceutical University, State Key Laboratory of Natural Medicine

Observed institutions: China Pharmaceutical University, Tongji Hospital, State Key Laboratory of Natural Medicine, Nanjing IASO Biotechnology Co., Ltd. (China), Huazhong University of Science and Technology

OpenAlex ID: A5113987160

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

2021 · Di Wang, Jue Wang, et al. · Blood · 204

Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice

2022 · Zongke Bai, Peiwei Yang, et al. · Cell Death and Disease · 42

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

2020 · Peiwei Yang, Ying Wang, et al. · Journal of the American Chemical Society · 27

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer

2023 · Peiwei Yang, Fan Yu, et al. · Cancer Immunology Immunotherapy · 22

Works count: 4

Citation count: 295

H-index: 4

I10-index: 4